NICE has released a new guideline on the use of Baricitinib in moderate to severe atopic dermatitis. Baricitinib is a Janus kinase (JAK) inhibitor.
As JAK is essential for certain cytokine signalling, by disrupting JAK, you disrupt cytokine signalling and thus disrupt the body’s immune response.
It will be used fourth line (after normal GP treatments, phototherapy and 1 other systemic immunosuppressant).